Coya Therapeutics, Inc. ( (COYA) ) has released its Q2 earnings. Here is a breakdown of the information Coya Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies to enhance the function of Regulatory T cells, primarily targeting neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases. In its latest earnings report for the quarter ending June 30, 2025, Coya Therapeutics reported a net loss of $6.1 million, compared to a net loss of $2.9 million in the same period last year. The company’s total operating expenses rose to $6.6 million, driven by increased research and development costs and general administrative expenses. Despite the financial losses, Coya continues to advance its development programs, with significant investments in research and development, including collaborations and licensing agreements. Looking ahead, Coya Therapeutics remains focused on securing additional financing to support its operations and advance its product candidates, as it anticipates further losses until it can achieve significant sales from its therapies under development.